Clinical Trials Browser

Completed × Mesothelioma × 1 year × Clear all

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT02662504 2026-02-05

MesoPDT

Phase 2 Completed

6 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

214 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03834272 2026-01-16

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

Phase 1/2 Completed

18 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Gastrointestinal Neoplasms, Mesothelioma, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05005429 2025-12-23

BIMES

Phase 2 Completed

47 enrolled 9 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT02611037 2025-12-18

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Phase 2 Completed

34 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT02875548 2025-11-04

TRuST

Phase 1/2 Completed

58 enrolled

LymphoidOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse

NCT05308966 2025-10-06

MESO-IMMUNE

Completed

204 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Phase 1/2 Completed

145 enrolled 47 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Phase 1 Completed

260 enrolled 52 charts

GastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT04153565 2025-07-17

MK-3475-A17

Phase 1 Completed

19 enrolled 14 charts

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma

NCT04242199 2025-07-14

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Phase 1 Completed

182 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Phase 1/2 Completed

316 enrolled

CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT02078700 2025-06-25